Peter G. C. Hansen, Graham D. F. Jackson – 1 September 1991 – The movement from blood to bile of passively injected autologous IgM antibody against horse erythrocytes was studied in rats. Both native and neuraminidase‐treated antibody entered bile intact, with the peak titers for both measured between 60 and 90 min after injection. A small part (0.38%) of the injected dose of native antibody and 1.05% of the asialo‐IgM antibody appeared in bile over 24 hr. These recoveries represented only a small fraction of the activity, which apparently disappeared from serum over the period.

Yannick Bacq, Christophe Gaudin, Antoine Hadengue, Dominique Roulot, Alain Braillon, Richard Moreau, Didier Lebrec – 1 September 1991 – The effects of dopamine on kidney function have not been elucidated in patients with cirrhosis. Moreover, although increased portal pressure has been observed with supradopaminergic doses of dopamine in these patients, the splanchnic hemodynamic effects of low doses of dopamine have not been previously studied.

1 September 1991

L. Siw Eriksson – 1 September 1991 – A 12‐year‐old boy with Wilson's disease developed exertional dyspnea, cyanosis, and finger clubbing 10 months after diagnosis. The hypoxemia was caused by arteriovenous shunting, demonstrated by radionuclide scanning and pulmonary arteriography. Orthotopic liver transplantation was performed after the development of severe hypoxemia. There was no apparent reversal of the intrapulmonary arteriovenous shunting and he died 10 days posttransplantation of multiple organ failure secondary to hypoxemia.

Gary L. Davis – 1 September 1991

J. Hilary Green, Peter N. Bramley, Monty S. Losowsky – 1 September 1991 – Wasting is common in end‐stage primary biliary cirrhosis and causes concern in patients facing liver transplantation. We have quantified resting metabolic rate and diet‐induced thermogenesis in seven patients with primary biliary cirrhosis, in seven patients after liver transplantation who had previously been diagnosed as having primary biliary cirrhosis and in seven controls.

Jean‐François Bretagne, Jean‐Luc Raoul, Michel Gosselin, Kunio Okuda, Kunio Kimura – 1 August 1991

Raymond S. Koff – 1 August 1991

John A. Hermos – 1 August 1991

Daniel W. Nebert – 1 August 1991 – These two reports describe recombinant DNA tests that can identify individuals having a defect in the cytochrome P450IID6 (CYP2D6)‐mediated oxidative metabolism of debrisoquine and more than two dozen other drugs that are commonly prescribed. The poor metabolizer (PM), representing 5% to 10% of the northern European white population is homozygous for an autosomal recessive trait. Compared with the extensive metabolizer (EM) phenotype, the PM individual is more prone to toxicity caused by some of these drugs.